✦ LIBER ✦

Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis

✍ Scribed by Anja Gunda Jung; Hans-Peter Horny; Karl Sotlar; Tobias Overbeck; Michael Peter Schön; Undine Lippert

Book ID: 116586012
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 454 KB
Volume: 65
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2009.11.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of imatinib mesylate as t

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

✍ Arturo Vega-Ruiz; Jorge E. Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintá 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 375 KB

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with ima

Imatinib mesylate responsiveness in aggr

Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation

✍ Bakul I. Dalal; Douglas E. Horsman; Hélène Bruyèrè; Donna L Forrest 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 1 views